ALMS

3.9608.55%
MB

Martin Babler

President, CEO & Chairman

Mr. Martin Babler, also known as Matt, Ph.D., is Independent Director of MapLight Therapeutics, Inc. from June 23, 2026. He serves as an Independent Director at 89bio, Inc. since April 13, 2024. He is Independent Member of Sardona Therapeutics, Inc. from May 2025. Mr. Babler was Chairperson of Sardona Therapeutics, Inc. until May 2025. He serves as President, Chief Executive Officer and Chairman of the Board at Alumis, Inc. (also knwon as Esker Therapeutics) since September 2021 and has been Director since September 2021. He is Independent Director at Neoleukin Therapeutics Inc. since September 2020. He serves as an Independent Director of Prelude Therapeutics Incorporated since July 2021. He serves as Independent Director at Omega Alpha Spac since January 2021. He served as the Chief Executive Officer of Principia Biopharma Inc since April 2011 until October 2020 and also served as its President from April 16, 2019 until October 2020. Mr. Babler served as the Chief Executive Officer and President of Talima Therapeutics Inc. from December 2007 to April 2011. He served as Senior Executive at Genentech where he served in various management positions from 1998 to 2007. He served as Vice President of Immunology Sales and Marketing of Genentech Inc. since June 2004. He joined Genentech in 1998 as a Director of Cardiovascular Marketing. During the next several years, he held positions as a Director and a Senior Director of Commercial Development and a Senior Director of Immunology Sales and Marketing. Mr. Babler was responsible for leading the strategic direction of the Immunology commercial area, including the management of sales and marketing efforts for Xolair(R) (Omalizumab) and market preparation for Rituxan(R) (Rituximab) for immune system disorders and product line extensions. He held several positions of increasing responsibility at Eli Lilly and Company. He served as a Director of Principia Biopharma Inc. until September 28, 2020. He served as a Director of ZS Pharma, Inc. from February 10, 2015 to December 16, 2015. He served as a Director of Talima Therapeutics, Inc. He served as Director of Infinity Pharmaceuticals, Inc. since May 2008 until March 6, 2014. Mr. Babler serves on the Emerging Companies Section and Health Section Governing Boards of the Biotechnology Innovation Organization, or BIO. Mr. Babler completed basic and advanced studies in pharmaceutical science and received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich, Switzerl. Mr. Babler is a graduate of the Executive Development Program at the Kellogg Graduate School of Management.

公司职务